title: Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
abstract: Despite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance remains the ultimate "Achilles' heel" for long-term durable remission in cancer patients. Acquisition of drug resistance is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and dasatinib, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially produces remission in the chronic phase, ultimately these therapeutics fail via the emergence of drug resistance, in which chronic myelogenous leukemia could inevitably progress to a terminal blast phase culminating in fatal outcome. Technically, it is challenging to predict the onset of drug resistance in a small number of oncogene-transformed cells, making the decision of when and how to employ second-generation tyrosine kinase inhibitors, or employ novel compounds that would be of benefit in treating drug-resistant Bcr-Abl mutants mainly retrospective. Here, we characterize a rapid and sensitive real-time fluorescent resonance energy transfer-based assay that is able to detect the in vivo activity of Bcr-Abl and its inhibition by small molecule compounds. Due to its real-time and in vivo nature, such an approach has the potential to monitor a drug-resistant phenotype, as well as to identify pharmaceutical agents that inhibit drug-resistant Bcr-Abl oncoproteins in vivo.
authors.affiliation: University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue MSB-E650, Newark, NJ 07103, USA. tuncerah@umdnj.edu
authors.forename: Ahmet
authors.initials: A
authors.lastname: Tunceroglu
authors.forename: Michiyuki
authors.initials: M
authors.lastname: Matsuda
authors.forename: Raymond B
authors.initials: RB
authors.lastname: Birge
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015374:Biosensing Techniques / Q000379:methods; D019556:COS Cells; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D003199:Computer Systems; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D008954:Models, Biological; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use; D013844:Thiazoles / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Mol Diagn Ther. 2006;10(2):67-76
references.pmid: 16669605
references.citation: Genes Dev. 1994 Apr 1;8(7):783-95
references.pmid: 7926767
references.citation: Nature. 1995 Mar 30;374(6521):477-9
references.pmid: 7700361
references.citation: Leukemia. 2010 Mar;24(3):658-60
references.pmid: 20010623
references.citation: Pharmacotherapy. 2008 Nov;28(11):1374-82
references.pmid: 18956997
references.citation: Cancer Res. 2002 Aug 1;62(15):4236-43
references.pmid: 12154025
references.citation: Blood. 2006 Jul 1;108(1):28-37
references.pmid: 16522812
references.citation: Science. 2000 Sep 15;289(5486):1938-42
references.pmid: 10988075
references.citation: Blood. 2007 Jan 15;109(2):500-2
references.pmid: 16990603
references.citation: Cancer Res. 2006 Jun 1;66(11):5790-7
references.pmid: 16740718
references.citation: Cancer Cell. 2002 Aug;2(2):117-25
references.pmid: 12204532
references.citation: Nat Rev Cancer. 2005 Mar;5(3):172-83
references.pmid: 15719031
references.citation: Hematology Am Soc Hematol Educ Program. 2002;:111-35
references.pmid: 12446421
references.citation: Curr Oncol Rep. 2001 May;3(3):223-7
references.pmid: 11296132
references.citation: Int J Clin Oncol. 2007 Oct;12(5):327-40
references.pmid: 17929114
references.citation: Mol Cell Biol. 1994 Aug;14(8):5192-201
references.pmid: 7518560
references.citation: Nat Struct Mol Biol. 2007 Jun;14(6):503-10
references.pmid: 17515907
references.citation: J Biol Chem. 2001 Aug 17;276(33):31305-10
references.pmid: 11406630
references.citation: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S113-9
references.pmid: 17382020
references.citation: Curr Pharm Biotechnol. 2006 Oct;7(5):371-9
references.pmid: 17076652
references.citation: Blood. 1995 Oct 15;86(8):3118-22
references.pmid: 7579406
references.citation: Int J Hematol. 2006 May;83(4):294-300
references.pmid: 16757427
references.citation: Nat Protoc. 2009;4(11):1623-31
references.pmid: 19834477
references.citation: Blood. 2008 Apr 15;111(8):4355-64
references.pmid: 18268096
references.citation: Leukemia. 2010 Jul;24(7):1375-8
references.pmid: 20508612
references.citation: Blood. 2007 Oct 1;110(7):2242-9
references.pmid: 17496200
references.citation: EMBO J. 1994 May 15;13(10):2341-51
references.pmid: 8194526
references.citation: Expert Opin Investig Drugs. 2010 Aug;19(8):931-45
references.pmid: 20557276
references.citation: Ann Intern Med. 2003 May 20;138(10):819-30
references.pmid: 12755554